Coronavirus and COVID-19
In various studies world-wide, scientists have examined a number of medicines to treat and prevent COVID-19. Some of them have already been used successfully to treat other virus infections and have been studied in clinical trials. All of these medicines must be re-evaluated scientifically for safety and efficacy in COVID-19. A combined use of multiple therapeutics is also conceivable.
Antibodies from persons who have recovered from a COVID-19 (convalescent plasma)
The administration of serum from persons who have recovered from COVID-19 to those infected with the virus, or, alternatively, purified antibodies against SARS-CoV-2 (so-called hyper-immunoglobulins) represents a passive form of immunisation. These antibodies bind and neutralise the virus and thus support the immune system in fighting the infection.
Immunotherapy with monoclonal antibodies
Anti-inflammatory monoclonal antibodies bind to surface molecules on cells and interrupt inter- and intracellular signalling pathways, e.g. via the interleuikin-6 receptor. The aim is to prevent or inhibit an exuberant immune response which is often observed in the course of COVID-19.
Mesenchymal stem cells
These cells are precursors for many different cell types in the human body. Their purpose is to have an anti-inflammatory effect in patients severely affected by COVID-19 following a transplantation, thus protecting lung tissue and regenerating damaged lung tissue. In Germany, they always require a manufacturing authorisation pursuant to the Good Manufacturing Practice (GMP) for the use in humans.
SARS-CoV-2 neutralising monoclonal antibodies
SARS-CoV-2 monoclonal antibodies bind structures on the virus or block receptors on human cells thus preventing the virus from entering the cell, the human immune response from overreacting, or the virus from interacting with the immune system.
Since February 2021, certain monoclonal antibodies against the SARS-CoV-2 coronavirus can be used in Germany as soon as they are available in Germany. In the meantime, these are, on the one hand, the antibodies Bamlanivimab and Etesevimab, which were developed by the US pharmaceutical company Eli Lilly. The other is the combination treatment with RegnCoV-2, consisting of the two antibodies Casirivimab/Imdevimab from the Swiss pharmaceutical company Roche and the US company Regeneron.
Product information Bamlanivimab/Etesevimab (German only)
Bamlanivimab/Etesevimab – Bamlanivimab: information for health care professionals (HCP) (As of 5 July 2021)
Bamlanivimab/Etesevimab – Etesevimab: information for health care professionals (HCP) (As of 5 July 2021)
Bamlanivimab/Etesevimab – Bamlanivimab: information for patients (As of 5 July 2021)
Bamlanivimab/Etesevimab – Etesevimab: information for patients (As of 7 May 2021)
Product information RegnCoV-2 (Casirivimab/Imdevimab) (German only)
Declaration of commitment by the responsible medical person (German only)
Report form on suspected side effects from monoclonal antibodies against COVID-19 (German only)
Antivirals inhibit the activity, structure, and replication of the virus in the human body (e.g. protease inhibitors, RNA-polymerase inhibitors).
Use of Monoclonal Antibodies against COVID-19
Monoclonal Antibody Cocktails against COVID-19 in Rolling Review
Paul-Ehrlich-Institut Approves First COVID-19 Therapy Study with Convalescent Plasma
RECOVER – the Paul-Ehrlich-Institut Authorises another COVID-19 Therapy Study with Reconvalescent Plasma
Recommendation of the Paul-Ehrlich-Institut for the Collection and Manufacture of COVID-19 Convalescent Plasma
Therapy against COVID-19 Symptoms under Development - Clinical Trials for Sarilumab authorised
Call for Blood Donations made by the PEI, Robert Koch Institute (RKI), and the Federal Centre for Health Education (BZgA) – Please observe the Appointments offered for Blood Donations!
RKI, Paul-Ehrlich-Institut and BZgA Call for Blood and Plasma Donations - Please Donate Even During Lockdown!